INTRODUCTION
Genetic deficiencies of the terminal complement (C)l components of man are rare, but their discovery has greatly enhanced the understanding of the role of C in host defense. Patients with deficiencies of C3 (2) (3) (4) and 6) , as well as with dysfunction of C5 (7, 8) , have an enhanced susceptibility to certain bacterial infections. In addition, patients with deficiencies of the C attack mechanism proteins C6 (9, 10), C7 (11) , and C8 (12) also seem to have a propensity to infections, particularly with bacteria of the Neisseria groups.
Three patients with inherited C7 deficiency have been the subject of complete reports. One was a 42-yrold womian with Raynaud's phenomenon, sclerodactyly, and telangiectasia (13) ; a second was a healthy 12-yrold boy (14, 15) ; and a third was a 44-yr-old woman (with two healthy homozygous siblings) with ankylosing spondylitis (16) . In addition, a family with three members lacking C7 has recently been presented in ' Abbreviations used in this paper: BSA, bovine serum albumin, C, complement; EA, antibody-sensitized sheep erythrocytes; GGVB, GVB diluted with an equal volume of 5% glucose; GVB, veronal-buffered saline containing 0.1% gelatin; HLA, human leukocyte antigens; C7D, C7-deficient; C3B-INA, C3b-inactivator; C567-INH, C567-inhibitors. which two of the deficient individuals sufferedl meninigococcal meniingitis in childhood and disseminated gonococcal infections as adults (11) , and we have recently observed a 28-yr-old woman with deficiency of CT7 and systemie lupus ervthematosus. 2 In this report, we describe an additioncal patienit with deficiency of C7 who presented with a history of recurrent uriniary tract infections anid end-stage renal disease, and emphasize the usefulness of hemolytic assays in agarose gels for the detection of this deficiency. In addition, we report both a propensity to C56 formation and the presence of an activitv inh ibitorv to C7 in the patient's serum with evidenee indicating that these phenomena are related. CASE REPORT C. A. was a 46-yr-old black woman who was hospitalized after 4 davs of severe low back paini which had occurred intermittently for 1 yr. She was known to have had hypertenision with suspected renal disease anid repeated uriniarv tract infections for approximately 7 vr, although no prior work-up had been undertakeni. She dlenied recenit dysuria, fre(luency, urgency, or changes in the color or (quantity of' urine. Both parents (now deceased) had renal disease and hypertension, anid her four children (ages 17-25 yr) are alive and well.
The patient was alert, well-developed, and obese on admission, with a blood pressure of' 160-130/130-100 mm Hg. Her physical examination was remarkable only for oculovascular changes characteristic of' hypertenisioni. The hemogram was normal, the erythrocyte sedimentation rate (WN'estergren) was 58 mm/h, and the C-reactive protein level was 16 ,ug/ml. Bone marrowv biopsy showed a hypocellular marrow which otherwise was normal.
The BUN level was 68 mg/ml (normal, 7-22 mg/ml) and the serum creatinine was 3.8 mg/ml (normal, 0.1-1.3 mg/ml). Urinalysis was normal except for 14 neutrophils anid 1-3 erythrocytes/high power field on mieroseopic examination; no casts were seen. A 24-h urine specimen contained 6.5 mg of total protein (normal, 2-1.50 mg) and decreased electrolytes. The creatinine clearance was 26 mg/min per m2 (normal, 80-110 mg/ min per m2). Urine cultures contained Proteus mirabilis (40,000 organissms/ml); multiple specimens of both urine and sputum were negative for acid-fLast bacteria. The serum uric acid level was 11.5 mg/dl (normal, 3-6 mg/ dl); inorganic phosphorous, 5.3 mg/dl (normal, 2.5-4.5 mg/dl; and vitamin B12, 87 pg/ml (normal, 300-1,000 pg/ml). The prothrombin time was 75% normal. Other blood chemistry evaluations were in or near the normal range. (17) .
Buffers. Veronal-buffered saline, pH 7.2, containing 0.1% gelatin (GVB) was prepared as previously described (17) . GVB was made to 10 mMN in EDTA (GVB-EDTA), or 1 mM in MgCl2 (GVB+). GVB diluted with an e(qual volume of .5% glucose and brought to 1mM MgCl2 and 0.15 mM CaCl2 (GGVBI3) was prepared as described (18) .
Eryttlrocyltes. Unsenisitized and senisitized sheep erythrocytes (E and EA, respectively), as well as guiniea pig erythrocytes vere prepared and stored as previously described (19 (20) . Total C hemolvtic activity andl assays for the hemolvtic activities of each of the Cl1-9 coiimponienits except C7, were performed as described (10, 20) . C7 first was assaved usinig purified C componieints. EACH (1 x 1(7), prepared according to Rapp and Borsos (21) , anidl having a Tmax of 5 min, were incuibatedl with 20 U each of' C2, C3, C5, and C6, andl serial (liltitions of test seriuim in 0.(1 ml GGVB'+ for In1herited C7 Deficiencyx in Alan 30 min at 30°C (total volume, 0.3 ml); 0.1 ml containing 15 U of both C8 and C9 in GGVB++ was added, and incubation was continued for 60 min at 37°C. The reaction was stopped by the addition of 1.0 ml of cold GVB-EDTA, the unlysed cells were removed by centrifugation, the absorbance of the supernate was determined at 412 nm, and the C7H50 was calculated. In later experiments, after the selective deficiency of C7 in the patient's serum had been established, C7 also was assayed using the serum of patient C. A. In this assay, EAC1423 (1 x 107), prepared according to Lachmann et al. (22) , were incubated with a 0.1-ml /5so dilution of patient C. A. serum and 0.1-ml serial dilutions of test serum in GGVB++ in a total volume of 0.3 ml for 90 min at 37°C. Lysis was quantitated and calculated as usual. The C7-consuming activity in C. A. serum (see below) did not interfere in this assay since the reactants were mixed in the cold (0°C) and C. A. serum was diluted two-fold beyond the level at which the activity inhibitory to C7 was detected during incubations at 37°C. Both assays yielded similar results when C7 activity was titered in either normal or half-normal (C7-deficient family members) sera.
Other assays. HLA typing was performed by microcytotoxicity assay as described (23) . Yeast phagocytosis was quantitated according to Miller and Nilsson (7) ; immune adherence C activity was measured according to the assay of Nishioka (24) ; and generation of activity chemotactic for neutrophils was generously assayed by Dr. John P. Leddy (Rochester, N. Y.) according to the method of Rosenfeld et al. (25) .
Hemolytic assays in gel. Screen plates containing EA were used for qualitative measurement of classical C-pathway hemolytic activity, and were prepared as described (10, 26) . Briefly, 1.0-ml 3% agarose (L'Industrie Biologique Francaise, Gennevilliers, France) dissolved in GVB+ and cooled to 60°C, was mixed with 2.5-ml of GVB+ containing 1 x 109 EA.
This mixture was poured into a 3.5-ml immunodiffusion plate (Hyland Diagnostics Div., Costa Mesa, Calif.), and after solidification, 2.1-mm diameter wells were prepared and filled with 5 il of the test sample. The plates were incubated for 1 h at 37°C, overnight at room temperature, and examined for lysis by inspection.
Plates containing E in the presence of 0.01 M EDTA were used to quantitate the generation of C56. These "reactor plates" were prepared by the addition of 1 ml 109 E in GVB-EDTA to a tube containing 1 ml 3% agarose (warmed to 60°C), 1 ml GVB-EDTA, and 0.5 ml guinea pig serum diluted Y5o in GVB-EDTA (17) . The mixture was rapidly poured into a 3.5-ml immunodiffusion plate, wells were prepared and filled with 5 ,ul of test samples, and the plates were incubated as described above.
C56 generation in normal, reactor, and C7-deficient serum.
Normal, reactor, and C7-deficient sera were tested for the presence of C56 after incubation with various C activators. 0.2-ml Sera and the activators were incubated for 60 min at 37°C, particulate material (inulin, agarose, and zymosan) was removed by centrifugation, and 5 ,lA of each mixture was applied to reactor plates for determination of the amount of C56 generated. A standard curve was prepared using partially purified C56 to allow the quantitation of the C56 generated in the different sera.
Assays for reconstitution of hemolytic activity and for C7 consuming activity. Reconstitution of hemolytic activity was demonstrated using the second of the C7 assays described above. Various Gel filtration of C. A. serum on Sephadex G-200. A 2.6 x 64-cm glass column was packed with Sephadex G-200 superfine and equilibrated with 0.1 M tris buffer, pH 7.5, which contained 0.09 M NaCl and 0.01 M EDTA. 5 ml ofC. A. serum was applied and chromatographed at a rate of7.3 ml/h and the A. and C7-consuming activity were determined in each 5-ml fraction, the latter by incubation of 50 jul of each fraction with 50 ,ul of purified C7 (1 U/tube) for 60 min at 37°C; residual C7 hemolytic activity was determined by the subsequent addition of 0.1 ml of each EAC1423 (107/tube) and C. A. serum (diluted Y1so), incubation at 37°C for 90 min, and quantitation of lysis in the usual way. The elution profiles of internal IgM, C3, C6, and albumin markers were determined by standard hemolytic or protein assays, while highly purified C56 was passaged through the column under identical conditions to determine its elution volume. Fractions with C7-consuming activity were pooled, concentrated by ultrafiltration on an Amicon PM-30 membrane (Amicon Corp., Scientific Sys. Div., Lexington, Mass.), and dialyzed against 0.01 M phosphase buffer, pH 7.5. Both the precipitate and supernate obtained by this procedure were assayed for C56 as described by Baker et al. (27) .
Adsorption of C7-deficient serum by anti-C5. 5 ml of Protein A-Sepharose CL-4B was mixed with 2 ml goat anti-human C5 (73 mg protein), rocked gently for 17 h at 4°C, poured into a 1.0 x 20-cm glass column, and washed extensively with 0.1 M phosphate buffer, pH 7.4. 0.2 ml of C7-deficient serum was applied to the immunoadsorbent, and the proteins which eluted with 0.1 M phosphate were pooled, concentrated to the original serum volume, and assayed for hemolytic C3 and C5 activities (10, 22) , as well as for C7-consuming activity as described above. Albumin, IgM, C3, and C5 protein concentrations were measured by radial immunodiffusion (20) . In separate experiments, both C56 and the partially purified C7-consuming activity were passed through identical anti-C5 immunoadsorbent columns and assayed for residual activity as just described.
RESULTS
The detection of abnormal serum by hemolytic assay in agarose gels. C. A. serum was found to totally lack hemolytic C activity. It was of interest that this C deficiency came to attention when a hemolytic C screen assay involving lysis of sensitized sheep erythrocytes embedded in agarose was performed, and the unusual pattern shown in Fig. 1 was observed. No primary lysis was seen around the well containing the patient's serum, although intense lines of "reactive lysis" concave to the patient's serum appeared within 24 h between the wells containing the patient and normal sera, respectively. These lines are indicative of the formation of an activated complex of C5 and C6 (C56), known to occur in sera which contain CS and C6 in excess of C7 upon interaction with the agarose contained in the indicator system (26) . The unusual pattern of this intense reactive lysis line in absence of a zone of primary lysis prompted further investigation of C. A. serum.
The complement profile in C. A. serum. Hemolytic C activity was lacking in fresh plasma as well as in FIGURE 1 The demonstration of the inability of patient serum (center well), in comparison to normal sera (surrounding wells), to induce primary lysis of sensitized sheep erythrocytes suspended in agarose gels; however, C56 was readily induced in patient serum as showin by the prominent lines of reactive lysis which formed between patient and normal sera. serum, and this was found to be attributable to a selective and apparently complete absence of C7 (Table I) . C component hemolytic activities of C1-9 with the exception of C7 were present in normiial or elevated amounts, and hemolytic activity w7as reconstructed by small amounts of highly purified C7 (Fig. 2) . The protein levels of C componienits Clq, C4, C3, C5, properdin, and properdin factor B were all present in normal or elevated amiiounits (Table I) , whereas C7 antigen was undetectable (<3 ,g/imil; normal, 60 ,ugg/ml) (28) . The C-dependent functionis of phagocytosis of yeast particles anid immuine adherenice, which require no C component acting later thani C3, as well as the generation of neutrophil chenmotactic activity, were normal in patient serum.
Inheritance of the C7 deficienici anid its relationiship to the HLA locus. Family studies were performed in order to define the genetics of the deficiency and its relationship to the inheritance of the HLA-A and HLA-B antigens. Normal levels of C7 established in a group of healthy adults showed a mean of 102,000 +23,000 U/ml, with a range of 73,000-140,000 U/ml.
As shown in Fig. 3 , both children in whom C7 levels were measured had approximately one-halfnormal values (40%-47%), three half-siblings had levels 30% normal, and a half-sister had an essentially normal (81%) C7 level. This pattern was consistent with autosomal codominant inheritance of the deficiency.
Only the Aw24 and B12 antigens were recognized at the HLA-A and HLA-B loci of the patient. However, another family member with this haplotype showed normal levels of C7, and two of the five family members with one-half normal levels of C7 lacked this haplotype. Thus, despite the detection of a single haplotype at the HLA-A and HLA-B loci, it would seem that the genes coding for the C7 protein in this family, as in the family reported by Delage et al. (16) , were inherited independently of those coding for the HLA antigens, but additional studies are needed to confirm this interpretation.
Pro pensityj to C56 getneration inl C. A. seruml. Persisting C56 can be generated in the serum of certain individuals unidergoinig inflammatory reactions upon incubation with variouis activators of the alternative pathway, at least in part becauise of a relative excess of C5 and C6 over C7 (29) . On this basis, the C7-deficient serum wvas expected to be particularly rich in its ability to develop C56 upon activation of the alternative C pathway, and this proved to be the case. Large amounts of C56 were readily generated upon incubation of C. A. serumii svith even small amotunts of activators of either the primary (aggregated human gamma globuliin, immuine complexes) or the alternative (inulin, agarose, zvlmiiosani, lipopolysaccharide) C pathw%ays (Table II) . Ildeed, the alternative pathwvay activators generated much imore C56 in C7-deficient serum thain in reactor serum, whereas amounts of primary pathway activators wvhich readily generated C56 in the C7-deficient serulm failed to generate C56 in the reactor seruimi at all. None of the activators were able to generate C56 inl norimial serulm (Table II) . Thus, the ease with wvhich C56 couild be generated in C7-deficient serumn was striking.
Demiionistrationi anid prelimimarl, descriptioni of the C7-consutmzing activitilj i C. A. serunm. C. A. sertum wxas tested for C7-constiming activity, in part because a "C7-inactivator" had beeni (lescribed in a previously reported patienit with C7 deficiency (15) . Incu)batioll of a smiiall amouinit (10 U) of C7 (either as the highly purified componieint or as diluted noriiail himiiaina serumii) with C. A. serum (1/5) for 30 min at 37°C resulted in the complete loss of' C7 activity. WVhen variouis amlouints of pturified C7 were preincubated at 37°C for 0-30 min vith a 1/30 diluition of C. A. serumiii and residuial C7 activity miieasuiredl in the uisuial wav, the I mr restults showvn in Fig. 2 Nvere observed. Wlith increasing preincubation timiies, inereasing amounts of C7 wvere required to achieve e(ltlivalent degrees of lysis. C7 incubated (30 mni Fig. 4 , the C7-consuminig activity eluitedl in a positionl identical to that of autthentic C56 passatged throuigh the colutmn11i uinder identical coniditions. The C7-consuming activity in C. A. plasimia also eltite(d in this position (data not showni).
To deteriniile whether the fractionis which had C7-consuminig activity also contained C56, aliquots were pooled, concentrated on ani Amilicon PM- 30 (17). The pooled fractions which showed C7-consuming activity also were found to contain significant amounts of C56. This was unlikely to have been generated from C5 and C6 during dialysis against the low ionic strength buffer, since the fractions with C7-consuming activity contained no detectable C6. Thus, C. A. serum and plasma contained C7-consuming activity which eluted identically to C56 on gel filtration and was associated with C56 activity in sensitive hemolytic assays. Adsorption of C7-consuming activity with anti-C5. To further explore the possibility that the C7-consuming activity was related to C56, C7-deficient serum was chromatographed over an immunoadsorbent column that was prepared with anti-C5 bound to Protein A-Sepharose CL-4B. More than 94% of the native C5 and 76% of the C7-consuming activity in whole serum was removed by this procedure; by contrast, no (<5%) C3, (<10%) albumin, or (<10%) IgM assayed as controls were removed by the immunoabsorbant (Table III) . In separate experiments, identical anti-C5 immunoadsorbants removed >92% of the purified C56 and 84% of partially purified C7-consuming activity when equivalent amounts of protein were passaged through the columns. Although passage of unfractionated or partially purified C7-deficient serum through the immunoadsorbent did not result in loss of all of the C7-consuming activity, it is significant that the majority of the activity was removed despite the presence of a vast excess of native C5 which would be expected to compete for sites on the column. Thus, these IgM <10 Albumin <10 * C7-deficient serum C. A. was passed through an immunoadsorbent column consisting of goat anti-human C5 coupled to Protein A-Sepharose CL-4B in the presence of 0.1 M phosphate; the eluate was concentrated to the original serum volume and assayed for hemolytic C3 and C5, as well as for C7-consuming activities. Albumin and IgM protein concentrations were measured by radial immunodiffusion. t Partially purified C56 and C7-consuming activities, respectively, were passed through identical anti-C5 immunoadsorbent columns in separate experiments. § The C7-consuming activity was partially purified by chromatography on Sephadex G-200. experiments indicated that the majority if not all of the C7-consuming activity was due to the presence of C56.
C7-consuming activity in sera from other C7-deficient individuals. Sera from two unrelated C7-deficient individuals, J. A. (13) and G. s.,2 were tested for the presence of C7-consuming activity using purified C7 as described above. No C7 activity or protein was demonstrable in J. A. serum, but serum from G. S. contained a small amount (0.2% normal) of hemolytically active C7. As shown in Fig. 5, J. A. serum displayed a degree of' C7-consuming activity similar to that seen in C. A. seruim; by contrast, only minimal C7-consuming activity was seen in serum from G. S. Since even small amounts of' C7 would react with and neutralize small amounts of C56 present in the C7D sera, these results are consistent with the concept that the C7-consuming activity is related to C56. This generalization is in keeping with earlier observations that C7-consuming activity of C. A. serum was detected only when limiting amounts of C7 were used in the assay procedure.
DISCUSSION
This paper describes a C7-deficient individual with recurrent urinary tract infections and chronic renal disease. The absence of C7 was inferred to result from a genetic defect in C7 synthesis because of half normal C7 levels in two children and several halfsiblings. All of the previously reported genetic deficiencies of C components have shown autosomal codominant inheritance, and the findings in this family are consistent with the same interpretation. Although only a single haplotype was detected at the major histocompatibility locus, raising the possibility of homozygosity for HLA as well as C7D, faamily studies FIGURE 5 Reconstitution of hemolytic activity in C7D J. A. and G. S. sera (0. suggested that the gene coding for synthesis of C7 protein was inherited independently of those coding for the HLA antigens. Since complete family studies could not be obtained, the data presented does not exclude the possibility of a distant linkage between HLA and C7 on chromosome 6, because one recombinant event could account for the single family member studied (the proband's half-sister 111-9) with the HLA haplotype Aw24/B12 and normal levels of C7. However, evidence presented in the investigations of two other C7-deficient individuals (16, 29) clearly showed a lack of linkage between HLA and C7, as clo recent studies on C7 polymorphism in man (30) . C7 deficiency was first reported in an individual with sclerodactyly and telangiectasia (13) , and then later in an apparently normal adolescent (14) , a 44-yrold lady with ankylosing spondylitis (16) , in several members of a family who have shown an unusual predisposition to gonococcal infections (11) , and in a 28-yr-old lady (G. S.) with systemic lupus erythematosus. Although there is no proof that the C7 deficiency was causally related to the symptoms observed in these individuals or in the patient described above, the present experience does extend the group of diseases with which patients with deficiency of C7 and thus, of the terminal complement components present. The clinical manifestations associated with this deficiency seem to be quite variable, and are consistent with the concept that the deficiency of C7, like deficiencies of the early acting C components, predispose to certain infectious and autoimmune processes.
A striking feature of the deficient serum was its propensity to form persisting C56 upon incubation with a variety of' C activators, i.e. to show the properties of a "reactor serum" (26 to persist, and this seems to have been the case in the patient presented herein. The propensity of the deficient serum to form C56 was reflected in the unusual pattern of lines of reactive lysis seen in absence of rings of primary lysis observed in the hemolytic reactions in agarose gels described above. This experience emphasizes the usefulness of assays in gel for detection of patients with deficiency of C7. We anticipate that such semiquantitative screening assays, because of their ease of performance, general accessability, and demonstration of unusual morphologic features such as those described above, will serve as usefuil adjuncts to the (juantitative hemolytic tube and protein assays, and will help to uncover patients with abnormalities of the complement system generally (20, 34) .
Initial studies of the deficient serum revealed an activity which consumed limited amounts of purified C7 as well as C7 in diluted serum or plasma; this occurred with time-and temperature-dependent kinetics and in the presence of EDTA, and persisted after heating at 56°C for 30 min. The propensity to form C56 in C. A. serum prompted further characterization of the C7-consuming activity with special attention to its relationship to C56, and four separate lines of experiments suggested that this activity was related to C56: (a), passage of the deficient serum through Sephadex G-200 showed that the C7-consuming activity co-chromatographed with purified C56; (b), fractions containing C7-consuming activity were found to contain significant amounts of hemolytically active C56; (c), substantial amounts of the C7-consuming activity in diluted serum and in partially purified form could be adsorbed with anti-C5; and (d) the C7-consuming activity was observed only in C7-deficient sera totally lacking C7. Taken together, these results indicate that the majority, if not all, ofthe C7-consuming activity present in C. A. serum is due to persisting C56. We cannot exclude the possibility that the C7-consuming activity may, at least in part, be attributable to a modified form of C56 which retains the ability to bind C7 (35) .
Wellek and Opferkuch (15) previously described a "C7-inactivator" in the serum of a C7-deficient individual which, although it had properties similar to many of those of the consuming activity found in the serum of our patient, was inferred to be distinct from C56. This was based upon its migration on Sephadex G-200, the lack of associated C56 activity, and an ability to inactivate C7 on a EAC1-7 intermediate. An activity with this latter property also was reported in two of four normal sera tested. These properties were assumed to derive from the same molecule and were offered as evidence for a new Cinhibitory principle termed the C7-inactivator. We do not know the basis for the difference between the results presented herein and the earlier studies of Wellek and Opferkuch. These authors did not (a) compare directly the elution profiles of purified C56 and their inhibitory principle on Sephadex G-200; (b) take into account the effects of inhibitors of reactive lysis (C567-INH) (17) which would markedly influence assays involving C56 and C7; or (c) consider additional factors such as the incompatibility of human and guinea pig terminal C component activities (36) . Based on the present studies, we would infer that the activity which they described might have been a manifestation of C56 and perhaps in certain assays also of C567-INH and (or) species incompatibilities and may not have represented a new C7 inhibitor. The reported absence of C7-inhibitory activity in C7-deficient serum by others (13, 16) probably is attributable to the degree of the deficiency (as cited above) and (or) to the type of C-consuming assay used, since both reports only involved assays for anti-total hemolytic C activities rather than for specific anti-C7 activity. Thus, whereas no inhibitory activity was demonstrated in C7-deficient serum J. A. in the initial report of this patient (13) , such activity was readily demonstrated in his serum by use of the specific C7 inhibition assay employed in the present study.
The studies presented herein thus reveal that C7-deficient serum has an unusually great propensity for the generation of persisting C56 upon incubation with activators of either the primary or the alternative C pathway. This is reflected in a distinctive pattern of lysis in gels which can be utilized for the rapid detection of C7 deficiency, and in the appearance of C7-consuming activity in serum and plasma which is associated with the presence and (or) ready formation of small amounts of C56. The biological advantage, if any, of this propensity to form persisting C56 is not yet clear.
